<p>1. Historical view</p> <p>Section I: Pathophysiology of prions<br>2. The cellular and pathological prion protein<br>3. Cell biology of prion infection<br>4. Experimental models of human prion diseases and prion strains<br>5. The role of the immune system in prion infection</p> <p>Section II: Animal prion diseases (clinical, epidemiology, neuropathological, biochemical, biomarker, and genotypes)<br>6. Typical and atypical scrapie<br>7. Typical and atypical BSE<br>8. Chronic Wasting Disease</p> <p>Section III: Human prion diseases (clinical, epidemiology, neuropathological, biochemical, biomarker, and genotypes)<br>9. Sporadic Creutzfeldt-Jakob Disease<br>10. Variably protease-sensitive prionopathy<br>11. Variant Creutzfeldt-Jakob Disease<br>12. Iatrogenic Creutzfeldt-Jakob Disease<br>13. Genetic Creutzfeldt-Jakob Disease<br>14. Gerstmann-Sträussler-Scheinker disease<br>15. Sporadic and fatal Familial Insomnia</p> <p>Section IV: Prion-like mechanisms in other neurodegenerative diseases<br>16. Prion-like mechanisms in Alzheimer<br>17. Prion-like mechanisms in Parkinson<br>18. Prion-like mechanisms in ALS </p> <p>Section V: Diagnosis and treatment<br>19. Prion protein amplification techniques<br>20. Differential diagnosis with other rapid progressive dementias<br>21. Symptomatic treatment, care and support of CJD patients<br>22. Identifying therapeutic targets and treatment in model systems<br>23. Vaccination strategies<br>24. Clinical trials</p> <p>Section VI: Public health issues<br>25. Animal diseases and the zoonotic potential<br>26. Safety of blood, blood derivatives and plasma-derived products<br>27. Safety in clinical practice<br>28. Concluding thoughts</p>